Multi-omic analysis and platelet function distinguish treatment responses to hydroxytyrosol in cardiovascular risk
Clara Noguera-Navarro, Kasper T. Vinten, David Auñón, Carmen Carazo-Díaz, Georges E. Janssens, Silvia Montoro‐García
Abstract
sp., respectively. Lipid metabolism and proteomic responses were heterogeneous within the two distinct subgroups, associated mainly with thrombotic and hemostatic signals. The metabolomic analysis further confirmed the differentially expressed metabolites within these two subgroups, highlighting improved glutathione metabolism after HT treatment. The omics datasets integration offers a more comprehensive representation of the glutathione and coagulation pathways affected by the HT treatment. Even though the translation of multi-omics technologies into the clinical landscape is slow, the current interventional study provides an overview of their utility in developing novel therapeutic opportunities to prevent CV diseases, such as suppression of platelet reactivity. Registration number of Clinical Trial: NCT06319417.